The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Moves on Peptides: What Compounding Pharmacies Need to Know FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Compounding warning letters to 503A facilities between 2017 and 2021 Journal of the American Pharmacists Association 18: peptides part II Carol Magalhes Isaacs